RBC Capital analyst Luca Issi reiterated a Hold rating on Bluebird Bio (BLUE – Research Report) yesterday and set a price target of $4.00. The company’s shares closed yesterday at $1.12.
According to TipRanks, Issi is an analyst with an average return of -22.8% and a 19.80% success rate. Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and BioMarin Pharmaceutical.
In addition to RBC Capital, Bluebird Bio also received a Hold from William Blair’s Sami Corwin in a report issued yesterday. However, today, Barclays assigned a Buy rating to Bluebird Bio (NASDAQ: BLUE).
The company has a one-year high of $5.53 and a one-year low of $0.85. Currently, Bluebird Bio has an average volume of 8.33M.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLUE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bluebird Bio (BLUE) Company Description:
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
